Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synovial Biopsy-Driven Therapy in Rheumatoid Arthritis
NCT05379322Phase 3Withdrawn
- Sponsor
- Abu Dhabi Stem Cells Center
- Start
- Mar 2023
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in rheumatoid arthritis (RA) (3 arms), sponsored by Abu Dhabi Stem Cells Center. Primary endpoint: Disease Activity Score 28 at 12 weeks. Planned start Mar 2023; status: withdrawn.
02
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05379322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05379322.